A colonoscopy has two lives under coding rules: a screening service with preventive benefits, and a diagnostic/therapeutic service once a polyp is found or symptoms documented. Medicare handles the transition with the PT modifier on the surgical code; commercial payers vary, and patient cost-sharing can swing by hundreds of dollars depending on how the claim is built.
Medicare's pathway is specific: a screening colonoscopy that converts to a therapeutic procedure (polypectomy, biopsy) bills the procedure code (e.g., 45385 for snare polypectomy) with modifier PT, indicating the screening became diagnostic. Without PT, the claim can trigger cost-sharing the patient should not owe under screening benefits — or deny for inconsistency with the preventive benefit logic. Commercial payers layer their own rules on top, which we verify per contract rather than assuming Medicare's pattern applies.
Code replacement is the second discipline. Therapeutic endoscopy codes inherently include the diagnostic examination — 45385 (colonoscopy with polypectomy) replaces 45378 (diagnostic colonoscopy); billing both is an NCCI denial by construction. Same for upper endoscopy: 43239 (EGD with biopsy) replaces 43235. Our scrubbing consolidates these pairs automatically, then checks that the replaced code matches the documentation's findings.
Finally, the findings loop. Payers audit screening claims against pathology and procedure notes; a screening claim with pathology-confirmed adenomas and no diagnostic code draws questions. We reconcile pathology results back into coding so screening claims reflect what was actually found — the difference between a preventable recoupment and a defensible chart.
“Consumers rarely appeal denied claims (fewer than 1% of denied claims were appealed), and when they do, insurers usually uphold their original decision (66% of appeals were upheld).”